Key Takeaways

• Market momentum continues via higher-dose semaglutide approval pathways and telehealth-oriented subscription programs that may broaden access while reshaping dispensing economics.
• Treatment discontinuation within year one commonly reflects combined financial burden and unexpected tolerability liabilities rather than loss of interest alone.
• Severe gastrointestinal adverse events, including nausea and vomiting, occur in an estimated 10–20% of users and can be sufficiently burdensome to precipitate cessation.
• Variability in weight-loss response, including minimal or absent benefit for some patients, undermines perceived value and accelerates discontinuation despite prior investment.